DRG Market Assessment 보고서

The availability of novel disease-modifying therapies (DMTs)—Copaxone 40 mg 3TW, oral DMTs, Plegridy, and Lemtrada—has complicated clinical decision-making and treatment choice in the…

Despite the extensive armamentarium of chronic pain therapies—and the fact that the market is increasingly subject to generics competition—the chronic pain market continues to represent a…

Bipolar disorder (BPD) is a debilitating psychiatric illness affecting more than 20 million people across the seven major pharmaceutical markets under study (United States, France, Germany, Italy,…

Mutations in the gene coding for C1-inhibitor (C1-INH) protein result in hereditary angioedema (HAE), whereby insufficient levels of C1-INH or abnormal forms of the protein ultimately result in…

Last updated 30 November 2015 Historically, developers of systemic lupus erythematosus (SLE) drugs faced formidable challenges: drug development for a complex, multifaceted, poorly understood…

Glioma, a type of tumor that affects the glial cells in the brain, is the most common form of central nervous system tumor. Astrocytic tumors are the most common histological subtype of glioma, and…

The U.S. Physician and Payer Perspectives on Novel Treatment Options for Prostate Cancer report surveyed 50 medical oncologists, 52 urologists, and 30 MCO pharmacy and medical directors to capture…

Mutations in the gene coding for C1-inhibitor (C1-INH) protein result in hereditary angioedema (HAE), whereby insufficient levels of C1-INH or abnormal forms of the protein ultimately result in…

China has the greatest burden of hepatitis B and liver cancer in the world. In 2014 chronic hepatitis B virus (HBV) infection affected nearly 89.8 million people in China; we expect the total…

Atopic dermatitis (AD), also known as (atopic) eczema, is a chronic, relapsing inflammatory skin disease marked by severe pruritus and skin irritation which can have a strong negative impact on…

ChartTrends: Rheumatoid Arthritis 2015 (US) provides insight into the management and treatment of RA patients by rheumatologists based on actual patient-level data. 224 U.S. rheumatologists…

LaunchTrends: Cosentyx (US) is a three-wave syndicated report series that specifically tracks the introduction of Novartis’s Cosentyx (secukinumab), a potent, subcutaneous IL-17 inhibitor…